Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals's stock reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.31). The company earned $10.40 million during the quarter, compared to analysts' expectations of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. Inovio Pharmaceuticals's revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.11) EPS. View Inovio Pharmaceuticals' Earnings History.

10 brokers have issued twelve-month price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $9.00 to $40.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $20.60 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Inovio reported narrower than expected loss in first quarter of 2017, with revenue beating estimates. Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Moreover, Inovio’s over-dependence on government grants and contracts for the development of its candidates is also concerning." (5/15/2017)
• 2. Maxim Group analysts commented, "Inovio reported 1Q17 with $10M in revenue (collaborations, partnerships) and operating expenses of $32M, for a net loss of $23M. The company ended the period with $90M, or ~three quarters of cash at the current burn rate." (5/11/2017)

Some companies that are related to Inovio Pharmaceuticals include Xencor (XNCR), Acceleron Pharma (XLRN), Epizyme (EPZM), Insys Therapeutics (INSY), Aimmune Therapeutics (AIMT), Forward Pharma A/S (FWP), ZIOPHARM Oncology (ZIOP), Achaogen (AKAO), Alder Biopharmaceuticals (ALDR), Cellectis SA (CLLS), Ascendis Pharma A/S (ASND), Immunomedics (IMMU), Five Prime Therapeutics (FPRX), Esperion Therapeutics (ESPR), La Jolla Pharmaceutical Company (LJPC), Albany Molecular Research (AMRI), Acorda Therapeutics (ACOR) and TG Therapeutics (TGTX).

Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.18%), State Street Corp (3.37%), Morgan Stanley (0.89%), Geode Capital Management LLC (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own Inovio Pharmaceuticals stock include Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, State Street Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., TIAA CREF Investment Management LLC, ProShare Advisors LLC and Bellevue Group AG. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Wells Fargo & Company MN, Vident Investment Advisory LLC, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $7.09.